Our Services
Medical Information
Helpful Resources
Published on: 9/24/2026
Yes, certain antidepressants can ease hot flashes, and several factors determine whether they are right for you, so see below for the complete answer. Low-dose SSRIs and SNRIs such as citalopram, escitalopram, paroxetine, venlafaxine, and desvenlafaxine have been shown to reduce the frequency and severity of hot flashes and night sweats, often within one to two weeks, making them a useful nonhormonal option for people who cannot or prefer not to take estrogen. Doses used for hot flashes are typically lower than those used for depression, and benefits vary by drug, with paroxetine and venlafaxine having the strongest evidence and paroxetine requiring caution in anyone taking tamoxifen. Possible side effects include nausea, dry mouth, dizziness, sleep changes, and sexual side effects, and these medicines should be tapered rather than stopped abruptly, so the details below are important before starting or switching. Because hot flashes can also stem from thyroid disease, medications, infection, anxiety, or other conditions, it is worth confirming what is actually driving your symptoms.
A free, instant, online symptom check takes only a few minutes, asks the same kinds of questions a clinician would, and helps you see which causes best match your pattern of hot flashes and what other symptoms may matter. Knowing that before your appointment makes it far easier to ask about low-dose citalopram or other options and to decide how soon you should be seen.
Last reviewed for medical accuracy: 09/24/2026
Hot flashes are one of the most common and disruptive symptoms of menopause and perimenopause. They can range from mild warmth to intense, drenching sweats that interfere with daily life and sleep. While hormone replacement therapy (HRT) remains the gold standard for relief, not every woman can or wants to use estrogen. In recent years, certain antidepressants—particularly selective serotonin reuptake inhibitors (SSRIs) like citalopram—have emerged as non-hormonal options for reducing hot flashes.
Below, we explain how citalopram works, review the evidence, discuss benefits and risks, and outline when to seek further medical advice.
Clinical Trials
Systematic Reviews
Professional Guidelines
While many tolerate citalopram well, common side effects include:
Rare but serious risks:
If you experience chest pain, severe dizziness, fainting, or rapid heartbeat, seek medical attention immediately.
| Treatment | Typical Reduction in Hot Flashes | Key Pros | Key Cons |
|---|---|---|---|
| Citalopram (SSRI) | 40–50% | Non-hormonal, mood lift | Takes weeks; side effects common |
| Paroxetine (SSRI) | 50–60% | FDA-approved for menopause | Sexual side effects |
| Venlafaxine (SNRI) | 50% | Quick onset (2 weeks) | Blood pressure elevation |
| Gabapentin | 45–55% | No sexual side effects | Dizziness, sedation |
| Clonidine | 30% | Low cost | Dry mouth, fatigue |
Medications work best when combined with healthy habits:
You should speak to a doctor if you experience:
For a quick, preliminary check, try a free, online symptom check, using the doctor approved Ubie Symptom Checker to see if your symptoms align with menopause or another condition.
Citalopram and other SSRIs/SNRIs offer a valuable non-hormonal option for many women struggling with hot flashes. While they don’t work as fast or as completely as HRT, they can significantly improve quality of life—especially for those who cannot take hormones.
Always weigh the benefits against potential side effects, and never start or stop any medication without discussing it with your doctor. If your hot flashes are intense, sudden, or accompanied by worrying symptoms, seek immediate medical advice, as they could signal a more serious issue.
Your health is unique—partner with your healthcare provider to find the best, safest approach for you.
(References)
* Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Johnston S, Rowe T, Sodhi N, Wilks P, Wolfman W, MENOPAUSE AND OSTEOPOROSIS WORKING GROUP. Managing menopause. J Obstet Gynaecol Can. 2014 Sep;36(9):830-833. doi: 10.1016/S1701-2163(15)30487-4. PMID: 25222364.
* Hill DA, Crider M, Hill SR. Hormone Therapy and Other Treatments for Symptoms of Menopause. Am Fam Physician. 2016 Dec 1;94(11):884-889. PMID: 27929271.
* Maki PM, Kornstein SG, Joffe H, Bromberger JT, Freeman EW, Athappilly G, Bobo WV, Rubin LH, Koleva HK, Cohen LS, Soares CN, Board of Trustees for The North American Menopause Society (NAMS) and the Women and Mood Disorders Task Force of the National Network of Depression Centers. Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. Menopause. 2018 Oct;25(10):1069-1085. doi: 10.1097/GME.0000000000001174. PMID: 30179986.
* Maki PM, Kornstein SG, Joffe H, Bromberger JT, Freeman EW, Athappilly G, Bobo WV, Rubin LH, Koleva HK, Cohen LS, Soares CN. Guidelines for the Evaluation and Treatment of Perimenopausal Depression: Summary and Recommendations. J Womens Health (Larchmt). 2019 Feb;28(2):117-134. doi: 10.1089/jwh.2018.27099.mensocrec. Epub 2018 Sep 5. PMID: 30182804.
* Landy K, Rosani A, Estevez R. Escitalopram. 2023 Jan. PMID: 32491666.
* Proserpio P, Marra S, Campana C, Agostoni EC, Palagini L, Nobili L, Nappi RE. Insomnia and menopause: a narrative review on mechanisms and treatments. Climacteric. 2020 Dec;23(6):539-549. doi: 10.1080/13697137.2020.1799973. Epub 2020 Sep 3. PMID: 32880197.
* Grigolon RB, Ceolin G, Deng Y, Bambokian A, Koning E, Fabe J, Lima M, Gerchman F, Soares CN, Brietzke E, Gomes FA. Effects of nutritional interventions on the severity of depressive and anxiety symptoms of women in the menopausal transition and menopause: a systematic review, meta-analysis, and meta-regression. Menopause. 2023 Jan 1;30(1):95-107. doi: 10.1097/GME.0000000000002098. Epub 2022 Nov 7. PMID: 36576445.
* Crandall CJ, Mehta JM, Manson JE. Management of Menopausal Symptoms: A Review. JAMA. 2023 Feb 7;329(5):405-420. doi: 10.1001/jama.2022.24140. PMID: 36749328.
* Lin KL, Talmor B, Crumbaker M, Joshua AM. A Review of Hot Flash Management in Patients With Prostate Cancer. J Clin Endocrinol Metab. 2025 Aug 7;110(9):2509-2519. doi: 10.1210/clinem/dgaf302. PMID: 40397707.
* Saadedine M, Banks V, Dinkel-Keuthage C, Janssenswillen C, Lavallee M, Moeller C, Schoof N, Vizcaya D, Francuski M, Golozar A, Römer T, Kubba A. Treatment patterns in women with breast cancer and endocrine therapy-related menopausal symptoms: a cohort study from the United States, United Kingdom, and Germany. Menopause. 2025 Dec 1;32(12):1111-1119. doi: 10.1097/GME.0000000000002611. Epub 2025 Dec 1. PMID: 40891646; PMCID: PMC12688460.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.